Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas
OBJECTIVE:The aim of this pilot study was to determine if metabolic tumor volume (MTV) and total lesion glycolysis (TLG) could serve as predictors of biochemical remission and pharmacotherapy-free interval in patients with metastatic pheochromocytomas (PCCs) and paragangliomas (PGLs). BACKGROUND:Patients with metastatic PCCs/PGLs have a high rate of biochemical recurrence, which can be associated with increased cardiovascular morbidity. Predictors of biochemical response are needed to guide and select patients who may benefit from therapy. METHODS:Whole body MTV and TLG was calculated from preoperative 18F-FDG PET/CT scans and analyzed as marker of biochemical response and pharmacotherapy-free interval. RESULTS:Seventeen patients underwent a total of 19 procedures, with a median follow-up time of 26.4 months. Whole body MTV of patients with biochemical recurrence (n = 13, mean 73.8 mL) was higher than those who had a biochemical response (n = 6, mean 14.7 mL, P = 0.05). Patients with low MTV (<37.2 mL) had an improved durable partial biochemical response (P < 0.05), and a statistical trend for complete biochemical remission (P = 0.07) and pharmacotherapy-free interval (P = 0.06). In 8 patients with metastatic disease outside the abdomen, 4 patients had less than 35% of their disease burden outside the abdomen and these patients had a more durable partial biochemical response compared to patients with greater than 35% of their disease burden outside the abdomen (P < 0.05). CONCLUSIONS:Whole body MTV and TLG represents novel and valuable predictors of biochemical response for patients with metastatic PCCs and PGLs. A larger prospective study should be performed to validate these findings..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:263 |
|---|---|
| Enthalten in: |
Annals of surgery - 263(2016), 3, Seite 582-587 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patel, Dhaval [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| RVK: |
|---|
| doi: |
10.1097/SLA.0000000000001018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1972680609 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1972680609 | ||
| 003 | DE-627 | ||
| 005 | 20240308193134.0 | ||
| 007 | tu | ||
| 008 | 160427s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1097/SLA.0000000000001018 |2 doi | |
| 028 | 5 | 2 | |a PQ20160430 |
| 035 | |a (DE-627)OLC1972680609 | ||
| 035 | |a (DE-599)GBVOLC1972680609 | ||
| 035 | |a (PRQ)c1778-5da7d7e57947d10dfbbe59d9e036097e9254e90e3b9d205eeed304ca506fd6e0 | ||
| 035 | |a (KEY)0036506820160000263000300582total18ffdgpetctmetabolictumorvolumeisassociatedwi | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a XA 23900 |q AVZ |2 rvk | ||
| 084 | |a 44.65 |2 bkl | ||
| 084 | |a 44.00 |2 bkl | ||
| 084 | |a 44.65 |2 bkl | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Patel, Dhaval |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a OBJECTIVE:The aim of this pilot study was to determine if metabolic tumor volume (MTV) and total lesion glycolysis (TLG) could serve as predictors of biochemical remission and pharmacotherapy-free interval in patients with metastatic pheochromocytomas (PCCs) and paragangliomas (PGLs). BACKGROUND:Patients with metastatic PCCs/PGLs have a high rate of biochemical recurrence, which can be associated with increased cardiovascular morbidity. Predictors of biochemical response are needed to guide and select patients who may benefit from therapy. METHODS:Whole body MTV and TLG was calculated from preoperative 18F-FDG PET/CT scans and analyzed as marker of biochemical response and pharmacotherapy-free interval. RESULTS:Seventeen patients underwent a total of 19 procedures, with a median follow-up time of 26.4 months. Whole body MTV of patients with biochemical recurrence (n = 13, mean 73.8 mL) was higher than those who had a biochemical response (n = 6, mean 14.7 mL, P = 0.05). Patients with low MTV (<37.2 mL) had an improved durable partial biochemical response (P < 0.05), and a statistical trend for complete biochemical remission (P = 0.07) and pharmacotherapy-free interval (P = 0.06). In 8 patients with metastatic disease outside the abdomen, 4 patients had less than 35% of their disease burden outside the abdomen and these patients had a more durable partial biochemical response compared to patients with greater than 35% of their disease burden outside the abdomen (P < 0.05). CONCLUSIONS:Whole body MTV and TLG represents novel and valuable predictors of biochemical response for patients with metastatic PCCs and PGLs. A larger prospective study should be performed to validate these findings. | ||
| 540 | |a Nutzungsrecht: Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 700 | 1 | |a Mehta, Amit |4 oth | |
| 700 | 1 | |a Nilubol, Naris |4 oth | |
| 700 | 1 | |a Dieckmann, William |4 oth | |
| 700 | 1 | |a Pacak, Karel |4 oth | |
| 700 | 1 | |a Kebebew, Electron |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of surgery |d Hagerstown, Md. : Lippincott, Williams & Wilkins, 1885 |g 263(2016), 3, Seite 582-587 |w (DE-627)129060569 |w (DE-600)340-2 |w (DE-576)014391260 |x 0003-4932 |7 nnns |
| 773 | 1 | 8 | |g volume:263 |g year:2016 |g number:3 |g pages:582-587 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1097/SLA.0000000000001018 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25405562 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-OEB | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | r | v | |a XA 23900 |
| 936 | b | k | |a 44.65 |q AVZ |
| 936 | b | k | |a 44.00 |q AVZ |
| 936 | b | k | |a 44.65 |j Chirurgie |j Chirurgie |q VZ |
| 936 | b | k | |a 44.00 |j Medizin: Allgemeines |j Medizin: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 263 |j 2016 |e 3 |h 582-587 | ||